Leukemia Clinical Trial
Official title:
Evaluation of Obatoclax Mesylate as Therapy for Patients With Systemic Mastocytosis
The goal of this clinical research study is to learn if obatoclax mesylate can help to control systemic mastocytosis. The safety of this drug will also be tested.
The Study Drug:
Obatoclax mesylate is designed to block the growth of malignant mast cells. This may cause
cancer cells to die.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will receive obatoclax
mesylate through a peripheral intravenous catheter (a needle in the vein of your arm). The
drug will be given over 3 hours each day on Days 1-3 of each 14-day study cycle.
If the study doctor thinks it is needed, you might receive the study drug though a
silicone-based central venous catheter (CVC). A central venous catheter is a sterile
flexible tube that will be placed into a large vein while you are under local anesthesia.
Some catheters cannot be used with the study drug. If you already have one of these
catheters in your body, it may need to be replaced before you can begin receiving the study
drug. You will sign a separate consent that will describe the procedure and its risks in
detail.
Study Visits:
One (1) time during each study cycle, the following tests and procedures will be performed:
- You will be asked about any side effects you may be having and about any other drugs
you may be taking.
- Blood (about 2 tablespoons) will be drawn for routine tests.
Every 3 months while you are taking the study drug, you will have a bone marrow
biopsy/aspirate to check the status of the disease.
Length of Study:
You will be able to continue receiving the study drug for as long as you are benefitting.
You will be taken off study if you have intolerable side effects or if the disease gets
worse.
Follow-Up:
Three months after your last dose of study drug, your doctor will call you to ask you how
you are feeling. This call should take about 10 minutes.
Additional Information:
- You must tell your doctor about any drug allergies you may have.
- You must tell your doctor about how much alcohol you consume and about any other drugs
you may be taking, including vitamins, herbal remedies, and over-the-counter,
prescription, and/or illegal drugs. Some of these will interact with the study drug.
- You must arrange to have someone drive you home after each treatment. You must not
drive or operate machinery (including kitchen appliances) after you have received the
study drug until any possible side effects have gone away.
- If you feel you any side effects or symptoms while you are on study, you must contact
your doctor right away.
This is an investigational study. Obatoclax mesylate is not FDA approved or commercially
available. At this time, obatoclax mesylate is only being used in research.
Up to 25 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |